FDA Continues Nanotech Policy Development With September Meeting
This article was originally published in The Gray Sheet
Executive Summary
FDA will hold a meeting next month to hear opinions on new guidelines in development on nanotechnology products, the agency announced Aug. 7 in the Federal Register
You may also be interested in...
Investors Seek Array Of Nanotechnology Projects To Finance
Health care nanotechnologies continue to be a hot prospect for venture capitalists and other investors, said investment managers March 26 at the PharmaMedDevice combination products meeting in Philadelphia
FDA Prepares To Issue Regulatory Guidance For Nanotechnology Devices
FDA should develop guidance for products that use nanotechnology and take steps to address the risks and benefits of the emerging technology, a July 25 agency task force report recommends
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.